Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Inventory (2020 - 2025)

Maxcyte (MXCT) has disclosed Inventory for 6 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 15.34% to $7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, down 15.34% year-over-year, with the annual reading at $7.5 million for FY2025, 15.34% down from the prior year.
  • Inventory for Q4 2025 was $7.5 million at Maxcyte, down from $7.6 million in the prior quarter.
  • The five-year high for Inventory was $12.5 million in Q3 2023, with the low at $4.1 million in Q3 2021.
  • Average Inventory over 5 years is $8.6 million, with a median of $8.3 million recorded in 2025.
  • The sharpest move saw Inventory soared 90.71% in 2022, then tumbled 30.82% in 2025.
  • Over 5 years, Inventory stood at $5.2 million in 2021, then surged by 64.87% to $8.6 million in 2022, then soared by 42.51% to $12.2 million in 2023, then decreased by 27.11% to $8.9 million in 2024, then dropped by 15.34% to $7.5 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $7.5 million, $7.6 million, and $7.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.